Literature DB >> 16434896

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Adebowale J Adeniran1, Zhaowen Zhu, Manoj Gandhi, David L Steward, James P Fidler, Thomas J Giordano, Paul W Biddinger, Yuri E Nikiforov.   

Abstract

Papillary carcinoma is the most common type of thyroid malignancy. It has been recently shown that these tumors commonly have one of three genetic alterations: BRAF point mutations, RET/PTC rearrangements, or RAS point mutations. In this study, we analyze the relationship between these alterations and the microscopic features of papillary carcinomas, their clinical features, and prognostic characteristics. Ninety-seven papillary carcinomas were studied; in all cases, frozen tissue was available for nucleic acid extraction. Of 96 unselected cases, 42% were positive for BRAF, 18% for RET/PTC, and 15% for RAS mutations. Morphologic features were evaluated in detail in 61 cases and 6 characteristic nuclear features and 3 additional microscopic features were assessed quantitatively. At least 4 nuclear features were found in each tumor, with nuclear pseudoinclusions being the least frequent finding in all mutation groups. BRAF mutations were associated with older patient age, typical papillary appearance or the tall cell variant, a higher rate of extrathyroidal extension, and more advanced tumor stage at presentation. RET/PTC rearrangements presented at younger age and had predominantly typical papillary histology, frequent psammoma bodies, and a high rate of lymph node metastases. Tumors with RAS mutations were exclusively the follicular variant of papillary carcinoma and correlated with significantly less prominent nuclear features and low rate of lymph node metastases. These findings demonstrate that BRAF, RET/PTC, and RAS mutations are associated with distinct microscopic, clinical, and biologic features of thyroid papillary carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434896     DOI: 10.1097/01.pas.0000176432.73455.1b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  121 in total

1.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

2.  The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.

Authors:  C Regalbuto; P Malandrino; F Frasca; G Pellegriti; R Le Moli; R Vigneri; V Pezzino
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

3.  Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant.

Authors:  Ian Ganly; Laura Wang; R Michael Tuttle; Nora Katabi; Gustavo A Ceballos; H Ruben Harach; Ronald Ghossein
Journal:  Hum Pathol       Date:  2015-02-04       Impact factor: 3.466

4.  BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.

Authors:  Giovanni Tallini; Dario de Biase; Cosimo Durante; Giorgia Acquaviva; Michele Bisceglia; Rocco Bruno; Maria Letizia Bacchi Reggiani; Gian Piero Casadei; Giuseppe Costante; Nadia Cremonini; Livia Lamartina; Domenico Meringolo; Francesco Nardi; Annalisa Pession; Kerry J Rhoden; Giuseppe Ronga; Massimo Torlontano; Antonella Verrienti; Michela Visani; Sebastiano Filetti
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

Review 5.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 6.  MicroRNA expression profiles in thyroid tumors.

Authors:  Marina N Nikiforova; Simon I Chiosea; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 7.  The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Authors:  Levent Gürbüzler
Journal:  Turk Arch Otorhinolaryngol       Date:  2016-04-06

8.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

9.  Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.

Authors:  Matthias Dettmer; Aurel Perren; Holger Moch; Paul Komminoth; Yuri E Nikiforov; Marina N Nikiforova
Journal:  Thyroid       Date:  2013-09-19       Impact factor: 6.568

10.  RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.

Authors:  Nikhil Gupta; Anil K Dasyam; Sally E Carty; Marina N Nikiforova; N Paul Ohori; Michaele Armstrong; Linwah Yip; Shane O LeBeau; Kelly L McCoy; Christopher Coyne; Michael T Stang; Jonas Johnson; Robert L Ferris; R Seethala; Yuri E Nikiforov; Steven P Hodak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.